Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 expression is negatively related to sorafenib sensitivity in HCC cell linws (Huh7, Hep3B, SNU-449, SNU-387). (A) Cell viability was examined by CCK-8 assay in four HCC cell lines subjected to sorafenib treatment. (B) Statistical analysis of the IC 50 in four HCC cell lines subjected to sorafenib treatment. (C) Relative mRNA levels of H19 as measured by RT-qPCR and normalized to β-actin in four HCC cell lines. (D) Cell proliferation was examined by EdU assay in four HCC cell lines subjected to sorafenib treatment. **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; IC 50 , half maximal inhibitory concentration.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Expressing, CCK-8 Assay, Quantitative RT-PCR, EdU Assay, Control, Concentration Assay

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 knockdown sensitizes HCC cells to sorafenib in vitro . (A) Sorafenib sensitivity of HCC cells transfected with NC siRNA or H19 siRNA. (B) Proliferative capacity of HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. **P<0.01, ***P<0.001, compared with the sorafenib group. (C) H19 expression in HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. *P<0.05, **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Knockdown, In Vitro, Transfection, Expressing, Control, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: H19 knockdown inhibits EMT and H19 positively regulates miR-675. (A) Immunofluorescence staining showed that E-cadherin (green) and vimentin (green) levels were altered after transfection of NC siRNA or H19 siRNA in the SNU-449 and SNU-387 cells. (B) E-cadherin and vimentin as assessed by western blot analysis. GAPDH was used as loading control. (C) Relative mRNA levels of miR-675 were measured by RT-qPCR and normalized to U6 after transfection of NC siRNA or H19 siRNA in four HCC cell lines. *P<0.05, **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; NC, negative control; EMT, epithelial-mesenchymal transition.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Knockdown, Immunofluorescence, Staining, Transfection, Western Blot, Control, Quantitative RT-PCR, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 regulates sensitivity of HCC cells to sorafenib. (A) Sorafenib sensitivity of HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor. (B) Proliferation of HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. ***P<0.001, compared with the sorafenib group. (C) Expression of miR-675 in HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. *P<0.05, **P<0.01, ***P<0.001. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Transfection, Expressing, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 alters EMT. (A) Immunofluorescence showed that the staining of E-cadherin (green) and vimentin (green) was altered after transfection with the miR-675 mimic, inhibitor, or NC siRNA in SNU-449 and SNU-387 cells. (B) E-cadherin and vimentin levels in HCC cells transfected with NC siRNA, miR-675 mimic, or miR-675 inhibitor in the presence of sorafenib. HCC, hepatocellular carcinoma; NC, negative control; EMT, epithelial-mesenchymal transition.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Immunofluorescence, Staining, Transfection, Negative Control

Journal: Oncology Reports

Article Title: Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675

doi: 10.3892/or.2020.7608

Figure Lengend Snippet: miR-675 mediates the regulatory effect of lncRNA H19 on sorafenib sensitivity. Sorafenib sensitivity of HCC cells transfected with NC siRNA or H19 siRNA was evaluated by CCK-8 assay in the presence of the miR-675 mimic for 48 h. HCC, hepatocellular carcinoma; NC, negative control.

Article Snippet: Human HCC cell lines (Huh7, Hep3B, SNU-449, SNU-387) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Transfection, CCK-8 Assay, Negative Control

Journal: Cell reports

Article Title: A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma.

doi: 10.1016/j.celrep.2023.112542

Figure Lengend Snippet: Figure 3. b-catenin facilitates the assembly of RNA spliceosome (A) IP assays of FUS in the KYSE140 cells with or without b-catenin silencing and Wnt3a treatment, followed by detection of b-catenin and splicing factors. (B) Western blot analysis of indicated spliceosome factors after MS2bs-based RIP assays in the DGCR5-E4-MS2bs-expressing KYSE140 cells with or without Wnt3a and b-catenin knockdown. (C) qRT-PCR analysis of DGCR5 exon-4 after RIP assays of SF1, U2AF65, and U2AF35 in the DGCR5-E4-MS2bs-expressing KYSE140 cells with indicated treatment. (D) IP assays of FUS in the Wnt3a-treated KYSE140 cells with or without the addition of RNase A, followed by detection of b-catenin and splicing factors. (E) FLAG-FUS and/or hemagglutinin (HA)-FUS-F3 (RRM-delta) were overexpressed in the KYSE140 cells. Cells were treated with Wnt3a and then subjected to IP assays of FLAG-FUS, followed by detection of indicated proteins. (F) RIP assays of SF1, U2AF65, and U2AF35 in the Wnt3a-treated KYSE140-DGCR5-E4-MS2bs cells with or without HA-FUS-F3 (RRM-delta) overexpression, followed by detection of DGCR5 exon-4. (G) qRT-PCR analysis of DGCR5-S in KYSE180, KYSE410, and KYSE450 cells transfected with NC or indicated small interfering RNAs (siRNAs). (H) A model shows the mechanism for b-catenin-induced splicing switch of DGCR5. Data in (C), (F), and (G) were plotted as the means ± SD of three biological triplicates. Unpaired two-sided Student’s t test was used in (C), (F), and (G). *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The human ESCC cell lines KYSE140, KYSE180, KYSE520, KYSE510, KYSE450, KYSE30, KYSE410, KYSE180, and KYSE150 were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany), the German Resource Center for Biological Material.64 THP-1 and WI-38 were obtained from ATCC.

Techniques: Western Blot, Expressing, Knockdown, Quantitative RT-PCR, Over Expression, Transfection